Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG0070 After Transurethral Resection in Patients With Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
NCT06253845Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cretostimogene grenadenorepvec in non-muscle-invasive bladder cancer (NMIBC), sponsored by Moffitt Cancer Center. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 years. Started Mar 2024; status: active, not recruiting.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06253845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253845.